MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
2.390
+0.010
+0.42%
After Hours: 2.330 -0.06 -2.51% 16:46 01/27 EST
OPEN
2.350
PREV CLOSE
2.380
HIGH
2.450
LOW
2.310
VOLUME
63.77K
TURNOVER
0
52 WEEK HIGH
7.55
52 WEEK LOW
1.940
MARKET CAP
12.17M
P/E (TTM)
2.232
1D
5D
1M
3M
1Y
5Y
Aptevo Therapeutics Files Provisional Patent For Fifth Bispecific Antibody APVO711, Intended For The Treatment Of Solid Tumors
Benzinga · 01/09 13:13
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 12/13/2022 17:14
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 12/13/2022 13:06
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Benzinga · 12/13/2022 12:54
Dow Surges Over 250 Points; Weber Shares Spike Higher
Benzinga · 12/12/2022 19:30
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Benzinga · 12/12/2022 18:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 12/12/2022 17:32
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
Benzinga · 12/12/2022 17:15
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. It has developed two platform technologies, such as ADAPTIR and ADAPTIR-FLEX for rational design of precision immune modulatory drugs. Its lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is being developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific CD3xCD123 ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate employing a mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

Webull offers kinds of Aptevo Therapeutics Inc stock information, including NASDAQ:APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.